SCD and metabolic dysfunction-associated steatohepatitis: The present study using WT and FXR KO mice has the following major novel findings: (1) Gyps treatment significantly improved liver histopathological abnormalities in HFD-induced NASH; (2) Gyps treatment decreased TG content in the liver and biochemical parameters associated with the dysregulation of lipid and glucose metabolism; (3) Gyps treatment significantly increased hepatic expression of FXR and its target SHP; and (4) Gyps treatment led to up-regulation of CPT1 and LPL, and down-regulation of SREBP1, FASN and SCD1 protein levels in WT mice but not FXR KO mice (Figure 10).